more

Quest Diagnostics (DGX)

(Delayed Data from NYSE)

$144.34 USD

+1.91 (1.34%)

Updated May 17, 2024 04:00 PM ET

After-Market: $144.33 -0.01 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.08%
2	Buy	17.91%
3	Hold	9.44%
4	Sell	5.10%
5	Strong Sell	2.55%
S&P	500	11.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth F Momentum C VGM

Industry Rank:

Top 24% (60 out of 249)

Industry: Medical - Outpatient and Home Healthcare

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Tandem Diabetes (TNDM) Q2 Earnings Miss, Sales View Cut

by Zacks Equity Research Published on August 04,2022

Factoring the pandemic and competitive pressure as well as the evolving economic environment, including inflation and the threat of recession, Tandem Diabetes (TNDM) cuts its full-year guidance.

CVS Health (CVS) Q2 Earnings Beat Estimates, Margins Down

by Zacks Equity Research Published on August 03,2022

CVS Health (CVS) posts better-than-expected results in Q2, with robust performances across all operating segments driving the top line.

Exact Sciences (EXAS) Q2 Earnings Top Estimates, Margins Down

by Zacks Equity Research Published on August 03,2022

Exact Sciences (EXAS) posts better-than-expected earnings and revenues in Q2 with robust performances across the Screening and Precision Oncology segments.

Charles River (CRL) Q2 Earnings Top Estimates, 2022 View Cut

by Zacks Equity Research Published on August 03,2022

Revenue decline in the CDMO business drag Charles River's (CRL) Manufacturing Solutions revenues down.

STERIS (STE) Q1 Earnings Match Estimates, EPS View Down

by Zacks Equity Research Published on August 03,2022

STERIS' (STE) revenues at AST improve driven by increased demand from medical device and biopharma customers.

Henry Schein (HSIC) Q2 Earnings Top Estimates, '22 EPS View Up

by Zacks Equity Research Published on August 02,2022

Henry Schein (HSIC) reports better-than-expected Q2 earnings with impressive sales growth across the Medical and Technology and Value-added Services segments.

DaVita (DVA) Beats on Q2 Earnings, Reiterates FY22 EPS View

by Zacks Equity Research Published on August 02,2022

DaVita (DVA) records an overall solid Q2 performance owing to strength in its Other segment's revenues and uptick in total U.S. dialysis treatments.

Zimmer Biomet (ZBH) Q2 Earnings Top Estimates, 2022 View Up

by Zacks Equity Research Published on August 02,2022

The contraction in Zimmer Biomet's (ZBH) gross margin is concerning.

IDEXX (IDXX) Q2 Earnings Surpass Estimates, 2022 View Down

by Zacks Equity Research Published on August 02,2022

IDEXX's (IDXX) Q2 top-line benefits from strong sales at the CAG and Water businesses.

Avantor's (AVTR) Stock Falls 8.8% Since Q2 Earnings Miss

by Zacks Equity Research Published on August 02,2022

Avantor's (AVTR) robust performance across majority of its segments drives its Q2 sales, despite business challenges.

Teleflex's (TFX) Q2 Earnings Top Estimates, 2022 View Down

by Zacks Equity Research Published on August 01,2022

For UroLift, Teleflex (TFX) witnesses revenue declines in all sites of service, including hospital, ASC and physician's office.

Chemed (CHE) Q2 Earnings Surpass Estimates, Margins Grow

by Zacks Equity Research Published on July 29,2022

Chemed (CHE) reports better-than-expected earnings in the second quarter, with a robust performance by the Roto-Rooter segment driving the top line.

Edwards Lifesciences (EW) Q2 Earnings Meet Estimates, Margins Up

by Zacks Equity Research Published on July 29,2022

Edwards Lifesciences (EW) posts Q2 earnings in line with the Zacks Consensus Estimate, with robust performances across all product groups driving the top line.

Amedisys (AMED) Q2 Earnings Surpass Estimates, Margins Down

by Zacks Equity Research Published on July 29,2022

Lower utilization of home health benefit, primarily driven by lesser total discharges to post-acute settings, hampers Amedisys' (AMED) Q2 revenues.

Bio-Rad (BIO) Q2 Earnings Surpass Estimates, Gross Margin Up

by Zacks Equity Research Published on July 29,2022

Overall demand for Bio-Rad's (BIO) Life Science and Clinical Diagnostics continues to be strong on localized surges of COVID-19.

Integer Holdings (ITGR) Q2 Earnings Miss, FY22 View Revised

by Zacks Equity Research Published on July 29,2022

Integer Holdings' (ITGR) second-quarter results reflect robust Medical Sales besides strength in the majority of product lines.